Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.
Tivantinib, an experimental oral inhibitor of the MET receptor, is not better than best supportive care in patients with inoperable hepatocellular carcinoma (HCC) who are intolerant or have previously received systemic therapy. ... Read more
Nanobiotix has named veteran pharmaceutical executive Alain Dostie as its chief operating officer. Among other functions, Dostie will lead the development, manufacturing, market access and sales of the French company’s ... Read more